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Abstract: IP3 receptor-binding protein released with IP3 (IRBIT) interacts with various ion channels
and transporters. An electroneutral type of sodium bicarbonate cotransporter, NBCn1, participates in
cell migration, and its enhanced expression is related to cancer metastasis. The effect of IRBIT on NBCn1
and its relation to cancer cell migration remain obscure. We therefore aimed to determine the effect
of IRBIT on NBCn1 and the regulation of cancer cell migration due to IRBIT-induced alterations
in NBCn1 activity. Overexpression of IRBIT enhanced cancer cell migration and NBC activity.
Knockdown of IRBIT or NBCn1 and treatment with an NBC-specific inhibitor, S0859, attenuated
cell migration. Stimulation with oncogenic epidermal growth factor enhanced the expression of
NBCn1 and migration of cancer cells by recruiting IRBIT. The recruited IRBIT stably maintained
the expression of the NBCn1 transporter machinery in the plasma membrane. Combined inhibition
of IRBIT and NBCn1 dramatically inhibited the migration of cancer cells. Combined modulation of
IRBIT and NBCn1 offers an effective strategy for attenuating cancer metastasis.
Keywords: IRBIT; migration; sodium bicarbonate cotransporter; cancer metastasis
1. Introduction
The inositol 1, 4, 5-trisphosphate (IP3) receptor-binding protein released with IP3 (IRBIT, also
referred to as AHCYL1) is a binding protein of IP3 receptor (IP3R) and mediates signaling events
with various receptors [1–3]. The released IRBIT from IP3R plays a role in regulating bicarbonate
secretion by interacting with and activating ion transporters, including cystic fibrosis transmembrane
conductance regulator (CFTR), sodium bicarbonate cotransporters NBCe1-B and NBCn1, sodium
hydrogen exchanger 3 (NHE3), chloride bicarbonate exchanger SLC26A6, and protein kinases, including
calcium/calmodulin-dependent protein kinase IIα (CaMKIIα) [2,4–6]. Moreover, the IRBIT suppresses
the activity of the IP3 receptor by competing with IP3 for the common binding site on the IP3 receptor [7].
The structure of IRBIT has been reported to possess an AHCY domain, coiled-coil domain, post synaptic
density 95/drosophila disc large tumor suppressor/zonula occludens-1 (PDZ) domain, and N-terminal
serine-rich region containing multiple phosphorylation sites [8,9]. IRBIT knockout mice with ovarian
cancer have behavioral abnormalities and defects in the secretory function of the pancreatic ducts,
suggesting that IRBIT has multiple in vivo functions [3,10].
Intracellular and extracellular pH homoeostasis are essential features of all cells, including cancer
cells. The metabolism of cancer cells is an essential process that produces acidic metabolic products,
including proton, lactate, and carbon dioxide [11]. The extracellular acidic pH affects proliferation,
migration, invasion, metastasis, and therapeutic response of cancer cells via transmembrane-associated
ion transporters and exchangers [12–16]. The electroneutral sodium bicarbonate cotransporter 1
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(NBCn1) is a member of the solute carrier 4 (SLC4) family of bicarbonate transporter proteins and
a major mediator of net cellular acid extrusion in most tissues [17–19]. The NBCn1 is expressed
in numerous cells and tissues, including the kidneys, heart, gastrointestinal tract, muscles, testes,
and brain [20–23]. NBCn1 mediates the uptake of bicarbonate ions in vascular smooth muscle
cells and promotes cell migration and proliferation [24,25]. It has been also reported that NBCn1
expression is related to breast cancer and is increased in primary breast carcinomas and metastasis
compared to normal breast tissue [26]. Moreover, NBCn1 promotes acid extrusion from breast
cancer cells, maintains an alkaline intracellular microenvironment, and facilitates aggressive tumor
development [27]. The cellular existence and development are associated with various ion channels
and transporters by maintaining factors such as cell volume, membrane potential, and acid–base
balance [28]. As a regulatory molecule, IRBIT binds and regulates the activity of ion channels and
transporters such as CFTR [2], NHE3 [29], and SLC26A6 [30]. IRBIT also stimulates the activity of
NBCs [2,30,31]. Although various binding partners of IRBIT have been identified, the physiological
relevance of the interactions between IRBIT and NBCn1 in cancer cell migration remains to be elucidated.
In addition, the information of role of IRBIT on tumor cells is relatively low. Thus, there is lots of
potential in cancer biology within the scope of transporter physiology and involvement of regulatory
proteins such as IRBIT in migratory machinery. We therefore aimed to investigate the role of IRBIT in
regulating cancer cell migration via modulation of NBCn1 activity. We also verified the role of IRBIT in
cancer cell migration by stimulation with oncogenic epidermal growth factor (EGF).
2. Materials and Methods
2.1. Plasmids and Cell Culture
Generation of the NBCn1 construct in pcDNA3.1 has been previously described [2]. cDNAs
encoding the full-length IRBIT and GFP-IRBIT proteins were subcloned into pcDNA3.0 and pEGFP-C1,
respectively. A549 lung adenocarcinoma cell line and HEK293T cells were obtained from the American
Type Culture Collection (Rockville, MD, USA) and maintained in Dulbecco’s modified Eagle’s medium
(DMEM, 11995073, Thermo Fisher Scientific, Waltham, MA, USA). MCF-7 cells were obtained from
the American Type Culture Collection (Rockville, MD, USA) and maintained in mammalian cell
culture medium (RPMI, A1049101, Thermo) supplemented with 10% fetal bovine serum (FBS, 1600-044,
Invitrogen, Carlsbad, CA, USA) and 100 U/mL penicillin-streptomycin (15140122, Invitrogen), and
incubated at 37 ◦C in a humidified incubator, in an atmosphere of 5% CO2 and 95% air. When
the cells reached 80% confluence, the culture medium was removed, and the cells were washed
with Dulbecco’s phosphate-buffered saline (DPBS, LB001-02, Welgene, Gyeongsan, Korea), followed
by treatment with trypsin/ethylenediaminetetraacetic acid (EDTA) for 5 min. The dispersed cells
were either transferred to fresh culture dishes for Western blotting, agarose spot assay, transwell
assay, and MTT assay, or transferred to fresh culture dishes with glass coverslips for imaging and
immunofluorescence experiments.
2.2. Agarose Spot Assay for Cell Invasion
Directional cell migration was examined by performing an agarose spot assay as previously
described [32,33], with modifications, in the chemotactic invasion assay protocol. Briefly, 10 mg of
agarose (UltraKem LE, Young Sciences, Bucheon, Korea) was placed in a 50 mL conical tube and
diluted with 2 mL of physiological salt solution A (PSA; (numbers indicate mM) 140 sodium chloride
(NaCl), 10 D-glucose, 5 potassium chloride (KCl), 1 magnesium chloride (MgCl2), 1 calcium chloride
(CaCl2), 10 HEPES (pH 7.4)) for preparing a 0.5% agarose solution, which was spotted onto 6-well
plates (Thermo) with four agarose spots per plate, and allowed to cool for 8 min at 4 ◦C. The cells
were then plated at a density of 4 × 105 cells/plate and allowed to adhere for 4 h before replacing
with a medium supplemented with 0.1% FBS (Invitrogen) and 100 unit/mL penicillin (Invitrogen) in
DMEM. The cell images were obtained after 4, 24, 48, and 72 h of incubation at 37 ◦C using the Meta
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Morph software (Molecular Devices, San Jose, CA, USA) with a 10× objective (Olympus, Tokyo, Japan).
The cells observed beneath the agarose spots represented the migrated cells and were counted.
2.3. MTT Assay for Cell Viability
A549 cells were cultured in 96-well plates at a density of 5 × 103 cells/well and were treated
with S0859 (18497, Cayman, Ann Arbor, MI). After the indicated incubation period, the medium
was replaced with MTT (3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyltetrazolium bromide, 2 mg/mL,
MT1036, BioPrince, Chuncheon, Korea) solution and the cells were incubated for 2 h at 37 ◦C.
The formazan crystals were dissolved by replacing with dimethyl sulfoxide (DMSO). The absorbance
was subsequently determined at 570 nm with a UVM 340 microplate reader (VICTOR X3, PerkinElmer,
Waltham, MA, USA).
2.4. Measurement of NBC Activity
The cells were attached onto coverslips and loaded with 6 µM 2′,
7′-bis-(carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF-AM, 0061, TEFlabs Inc, Austin,
TX, USA) along with the same volume of 0.05% pluronic acid (P-3000MP, Invitrogen) for 15 min at room
temperature (RT). After incubation with the BCECF dye, the cells were perfused with physiological
salt solution, as previously described [34], for at least 5 min prior to determining the intracellular pH
(pHi). pHi was determined by measuring BCECF fluorescence using dual excitation wavelengths of
495 and 440 nm, and an emission wavelength of 530 nm. NBC activity was measured by incubating
the cells with a CO2-saturated HCO3— buffered ((numbers indicate mM) 120 NaCl, 10 D-glucose,
5 KCl, 1 MgCl2, 1 CaCl2, 2.5 HEPES (pH 7.8]) 25 sodium bicarbonate (NaHCO3)) medium containing
5-(N-ethyl-N-isopropyl)-amiloride (EIPA, 1154-25-2, Sigma Aldrich, Saint-Louis, MO, USA), followed
by acidification with an Na+-free HCO3−-buffered medium. Images were obtained with a CCD
camera (Retiga 6000, Q-Imaging) attached to an inverted microscope (Olympus) and analyzed with
a Meta Fluor system (Molecular Devices). The images were individually normalized by subtracting
the background fluorescence from the raw background signals.
2.5. Treatment with Small Interfering RNA (siRNA) and DNA Transfection
siRNA for human IRBIT was produced using Double-Promoter pFIV-H1/U6 siRNA cloning and
expression vectors (SI111A-1, System Biosciences, Palo Alto, CA, USA), according to the instructions
provided with the kit. The purified plasmids contained the human siRNA-IRBIT sequence (sense:
5′-AAA GGG CCA TGA ACG TCA ATG ATT CTG TTA C-3′; and antisense: 5′-AAA AGT AAC AGA
ATC ATT GAC GTT CAT GGC C-3′) and siRNA-NBCn1 sequence (sense: 5′-AAA GGT GGG ATC
CTT CTA TAC GCA TAG AA-3′; and antisense: 5′-AAA ATT CTA TGC GTA TAG AAG GAT CCC
ACC TT-3′). A549 cells were transfected with 1 µg of the siRNA vectors. The siRNA vectors were
diluted with 200 µL of Opti-Eagle’s minimum essential medium (Opti-MEMTM, 31985-070, Invitrogen)
and mixed with Lipofectamine 2000 DNA transfection reagent. The mixture was incubated at RT
for 25 min, transferred to cell dishes containing culture media, and cultured for 4 h. The transfected
medium was replaced with fresh culture medium supplemented with FBS, and the cells were used
after 48 h of transfection. The plasmid DNA was transfected with Lipofectamine 2000 according to
the manufacturer’s protocol (11668019, Invitrogen). The plasmid DNA was individually diluted with
200 µL of Opti-MEM, to which 4 µL of Lipofectamine 2000 was added, and the mixture was incubated
for 5 min at RT with 200 µL of the same medium. After 25 min, the DNA samples and Lipofectamine
2000 were mixed and added to the cell culture dish containing glass coverslips. Following 4 h of
incubation, the medium was replaced with fresh DMEM supplemented with 10% FBS, and the cells
were cultured for 24 h (for DNA transfection) or 48 h (for siRNA transfection) after transfection.
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2.6. Immunofluorescence and Confocal Imaging
A549 cells were transferred onto cover glasses and fixed with chilled (−20 ◦C) methanol. The fixed
cells were treated with 5% goat serum (in DPBS) for 1 h at RT for blocking the non-specific binding
sites. The cells were incubated overnight with primary antibodies at 4 ◦C, followed by washing
thrice with the incubation buffer (5% BSA in DPBS). The NBCn1 (ab82335, Abcam, Cambridge,
UK) antibody was detected by treating the cells with secondary antibodies, rhodamine-tagged goat
immunoglobulin G (IgG) (Jackson ImmunoResearch, West Grove, PA, USA, anti-mouse: 115-025-072,
anti-rabbit: 111-025-144), and fluorescein isothiocyanate (FITC, Jackson ImmunoResearch, anti-mouse:
115-095-071, anti-rabbit: 111-095-003) for 1 h at RT. Following incubation, the cells were washed thrice
with DPBS, and the cover glasses were mounted on glass slides using 20 µL of Fluoromount-GTM
containing 4′,6-diamidino-2-phenylindole (DAPI, 17984-24, Electron Microscopy Sciences, Hatfield,
PA, USA), and incubated overnight at 4 ◦C. The slides were then analyzed using an LSM 700 Zeiss
confocal microscope (Carl Zeiss, Germany) with ZEN software (Carl Zeiss, Oberkochen, Germany).
2.7. Surface Biotinylation, Co-Immunoprecipitation, and Western Blotting
The cells that had been transfected with siRNA and treated with S0859 (18497, Cayman) were
incubated with 1× lysis buffer (9803, Cell signaling, Danvers, MA, USA) containing 20 mM Tris,
150 mM NaCl, 2 mM EDTA, 1% Triton X-100, and a protease inhibitor mixture that had been prepared
by passing cell lysates after sonication. The cells were centrifuged at 11,000× g for 15 min at 4 ◦C,
and the protein concentration was determined by Bradford assay (5000001, Bio-Rad, Hercules, CA,
USA). For co-immunoprecipitation (Co-IP), the supernatant was treated with 1 µg/mL of the indicated
antibodies at 4 ◦C for 16 h with gentle shaking, followed by incubation with agarose G protein beads
(Santa Cruz, Dallas, TX, USA) for 4 h. The mixture was subsequently centrifuged at 11,000× g for
2 min at 4 ◦C and washed twice with the lysis buffer at 4 ◦C for 10 min. The beads were incubated in
the sample buffer at 37 ◦C for 15 min for detaching the proteins. The eluted proteins were analyzed
by Western blotting. To demonstrate the surface expression of the proteins, the transfected cells were
incubated with 0.5 mg/mL EZ-LINK sulfo-NHS-LC-biotin (21335, Thermo) for 30 min on ice, followed
by treatment with 100 mM of cold glycine solution for 10 min. The incubated cells were washed
with DPBS and incubated with the lysis buffer. The cell extracts were centrifuged at 11,000× g for
15 min at 4 ◦C, and the cellular debris was discarded. The supernatants were incubated overnight
with 80 µL Avidin beads (20347, Thermo) at 4 ◦C, followed by washing the beads with the lysis
buffer. The collected beads were incubated with a protein sample buffer at 37 ◦C for 15 min for
recovering the proteins. The warmed protein samples (30 µg) were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride
(PVDF, 1620177, Bio-rad) membranes soaked in methanol. The membrane was blocked with 5% non-fat
milk solution in TBS-T (Tris-buffered saline (TBS) and 0.5% Tween-20) for 1 h. The membrane was
subsequently incubated overnight with β-actin (A5441, Sigma, Saint-Louis), IRBIT (10658-3, Proteintech
Group Inc, Rosemont, IL, USA), NBCn1 (ab82335, Abcam), GFP (ab6556, Abcam), and HA-tag (C29F4,
Cell signaling) antibodies at 4 ◦C, and washed thrice with TBS-T. After washing, the membranes
were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit secondary
antibodies, and the protein bands were visualized using an enhanced luminescent solution (32209,
Thermo).
2.8. Transwell Membrane Immunostaining
Directional cell migration was examined by performing a transwell membrane immunostaining
with Boyden chamber as previously described [35,36]. A549 cells (200 µL, 5 × 104 cells) were cultured
in each well of the upper chamber of 6-well plate. The bottom chambers were filled with pH 7.4 media,
S0859, or EGF along with 1% FBS added to DMEM (500 µL). After incubation for 6 h, the membrane
was subsequently stained with DAPI or crystal violet. Briefly, chilled methanol (−20 ◦C) was added
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to the plates and the cells were incubated for 1 min. The methanol was removed, and the cells were
washed with DPBS. DAPI solution, mixed with distilled water (DW), was added to the plates, and
the cells were incubated for 30 min in the dark. The media were carefully removed from the top and
bottom plates. DW was added to the plates at RT and measured at 340 nm using an LSM 700 confocal
laser scanning microscope (Carl Zeiss, Germany). Migration of the A549 cells after 6 h was determined
by evaluating the number of nuclei that were stained with DAPI on the transwell membrane. For
crystal violet staining, 0.25% crystal violet was added to the plate and the membrane was incubated
for 15 min at RT. The crystal violet was subsequently removed, and the membrane was washed with
DPBS. The medium was carefully removed from the top and bottom plates, following which DW was
added to the plate and incubated for 30 min at RT. The plate was subsequently analyzed using an LSM
700 Zeiss confocal microscope (Carl Zeiss) with Mosaic software (Opto Science, Tokyo, Japan).
2.9. Scratch Wound Healing Assay
Scratch wound healing assay was performed according to previously described [37,38]. A549 cells
(5 × 104 cells) were cultured in 6-well plate. When the cell confluence reached about 80% and above
and scratch wounds were produced with 1000 µL pipet tips in each well. After scratching, the cell
debris was removed and the cell images were obtained after 0, 24, 48, and 72 h of incubation at 37 ◦C,
using the 700 Zeiss confocal microscope (Carl Zeiss) with Mosaic software (Opto Science).
2.10. Statistical Analyses
All data from the indicated number of experiments were expressed as the mean ± standard error
of the mean (SEM). The statistical differences between mean values obtained from the two or more
sample groups were analyzed using paired Student’s t-test. Two independent sample datasets come
from distributions with different of two different groups. Statistical significance was determined by
analysis of variance for each experiment (* p < 0.05, ** p < 0.01, *** p < 0.001).
3. Results
3.1. IRBIT Enhanced Cell Motility via NBC
In order to demonstrate the role of IRBIT in cancer cell invasion and motility, we modified
the agarose spot migration assay as previously described in our benchmark study [32]. Exposure of
cancer cells to the microenvironment is known to increase tissue rigidity during tumor development
and progression [39,40]. This assay provides a more rigid environment than that of the culture
media and effectively mimics the microenvironment of cancer cells, allowing the function of cellular
invadopodia to be studied more precisely. The migration ability of cells in the agarose spot was
determined. The experimental scheme is presented in Figure 1A,B. In order to verify the role of NBC
in the migratory function of cancer cells, the activity of NBC was measured in region of interests
of two regions, namely, the migration area and steady area. The activity of NBC in the migration
area was found to be 2-fold higher than that in the steady area (Figure 1C,D). To explore the role of
IRBIT on cell migration, the motility of the invasive A549 cells in the agarose spots was compared
between the control and IRBIT-overexpressed conditions (Figure 1E). It was observed that, on average,
the invasive motility of IRBIT-expressing A549 cells was approximately 1.4-fold higher than that of
the control cells (Figure 1F). We also confirmed the migration assay with DAPI and crystal violet to
verify the efficacy of IRBIT plasmids (Supplementary Figure S1A–D) and enhancement of migration of
IRBIT by scratch wound healing assay (Supplementary Figure S2A–C). IRBIT recruits NBCe1-B and
enhances the activity of NBC [31]. To explore the role of the transporter in cell motility, NBC imaging
was performed. The role of IRBIT in regulating NBC activity was investigated by studying the activity
of NBC in IRBIT-overexpressing A549 cells. NBC activity was enhanced in the IRBIT-overexpressing
cells (Figure 1G,H). There was no difference between the two groups with respect to the resting pHi
level (Figure 1I). These results suggested that IRBIT enhanced cell motility by increasing NBC activity.
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is indicated by a dashed curve. The red dotted lines indicate the lineage of cells that migrated 
toward the agarose spots. (B) Schematic illustration of agarose spots containing PBS (pH 7.4), with 
the red dotted lines indicating the region of interest (ROI) of migration area, and the blue dotted 
lines indicating ROI of steady area. (C) NBC activity in migration state (violet open square) and 
steady state (black open square) of A549 cells in the agarose spots at 48 h. Averaged traces are 
presented. (D) The bars indicate the mean ± SEM of data obtained from five experimental replicates 
(n = 5). (E) Time-dependent representative images of the migration of A549 cells toward the agarose 
spots containing PBS (pH 7.4), with or without IRBIT. (F) Analysis of the migration range per hour. 
The bars indicate the mean ± SEM of data (n = 10). (G) NBC activity in the A549 cells with (red open 
square) or without (control, black open square) IRBIT at 48 h. Averaged traces are presented. (H) The 
bars indicate the mean ± SEM of data (n = 5). (I) The bars depict the resting pHi level of A549 cells and 
indicate the mean ± SEM of data (n = 30). 
Figure 1. IRBIT enhanced cell motility via NBC. (A) Time-dependent representative images of
the migration of A549 cells toward the agarose spots containing PBS (pH 7.4) for indicated times.
The blue dotted lines indicate the direction of migration across the boundary of the agarose spot, which
is indicated by a dashed curve. The red dotted lines indicate the lineage of cells that migrated toward
the agarose spots. (B) Schematic illustration of agarose spots containing PBS (pH 7.4), with the red
dotted lines indicating the region of interest (ROI) of migration area, and the blue dotted lines indicating
ROI of steady area. (C) NBC activity in migration state (violet open square) and steady state (black
open square) of A549 cells in the agarose spots at 48 h. Averaged traces are presented. (D) The bars
indicate the mean ± SEM of data obtained from five experimental replicates (n = 5). (E) Time-dependent
representative images of the migration of A549 cells toward the agarose spots containing PBS (pH 7.4),
with or without IRBIT. (F) Analysis of the migration range per hour. The bars indicate the mean ± SEM
of data (n = 10). (G) NBC activity in the A549 cells with (red open square) or without (control, black
open square) IRBIT at 48 h. Averaged traces are presented. (H) The bars indicate the mean ± SEM of
data (n = 5). (I) The bars depict the resting pHi level of A549 cells and indicate the mean ± SEM of data
(n = 30).
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3.2. IRBIT Co-Localized with NBCn1 and Modulated the Membrane Expression of NBCn1
NBCn1 is closely associated with the cancer microenvironment and is necessary during
development of cancer [27]. To investigate the protein–protein interactions and colocalization between
IRBIT and NBCn1, we determined the effect of IRBIT on the interaction and immunolocalization
of NBCn1 in HEK293T cells. As depicted in Figure 2A, Co-IP data show the interaction between
IRBIT and NBCn1. Additionally, A549 cells were separately immunostained with NBCn1 and IRBIT.
In order to ensure that there were no artifacts from the same host during co-localization of the two
proteins, the cells were overexpressed GFP-IRBIT. It was observed that NBCn1 localized in the plasma
membrane, and IRBIT co-localized with NBCn1 (Figure 2B,C). The membrane localization and surface
expression of NBCn1 were enhanced by IRBIT (Figure 2D–F). In order to confirm that IRBIT enhanced
the activity of NBCn1, HEK293T cells were transfected with NBCn1. The IRBIT increased NBC activity
in the cells that overexpressed NBCn1 (Supplementary Figure S3A,B). The results suggest that IRBIT
enhanced cell motility by increasing the activity of NBCn1.
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Figure 2. IRBIT co-localized with NBCn1 and modulated the membrane expression of NBCn1. (A)
Co-IP of NBCn1 and IRBIT in HEK293T cells. Cells were transfected with HA-tagged NBCn1 and
GFP-tagged IRBIT, immunoprecipitated with GFP antibody, and blotted with NBCn1 antibody. β-Actin,
input HA, and input GFP blots were used as loading controls (n = 3). (B) Immunostaining images of
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NBCn1 (red), GFP-IRBIT (green), and nucleus (DAPI, blue) in A549 cells. The scale bars represent
20 µm. (C) Magnified images of the dotted lines. (D) Analysis of NBCn1 intensity in the membrane
expression. The bars indicate the mean ± SEM (n = 5). (E) Surface expression of NBCn1 in the presence
of IRBIT in A549 cells. Input β-actin and input NBCn1 blots were used as loading controls. (F) The bars
indicate the mean ± SEM of relative NBCn1 intensity normalized by input NBCn1 (n = 3).
3.3. IRBIT Knockdown Decreased Cell Motility and NBC Activity
To verify the role of IRBIT on NBC activity, cells were transfected with SiRNA-IRBIT. The efficacy
of SiRNA-IRBIT was evaluated by Western blotting (Figure 3A,B). The invasive motility of the cancer
cells was inhibited by IRBIT knockdown (Figure 3C,D). IRBIT knockdown dramatically inhibited
the activity of NBC (Figure 3E,F). The resting pH value of cells with SiRNA-IRBIT was lower than that
of the control (Figure 3G). The surface expression (Figure 3H) and membrane localization (Figure 3I,J)
of NBCn1 decreased in the presence of SiRNA-IRBIT. IRBIT knockdown reduced the activity of NBC
and the membrane localization of NBCn1, suggesting that IRBIT is involved in stabilizing NBCn1 on
the plasma membrane for cell migration.
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(B) Analysis of IRBIT expression in the presence of SiIRBIT in A549 cells. The bars indicate the mean ±
SEM of data (n = 5). (C) Time-dependent representative images of the migration of A549 cells toward
the agarose spots containing PBS (pH 7.4), with or without SiIRBIT for indicated times. (D) Analysis of
migration range per hour. The bars indicate the mean ± SEM of data (n = 6). (E) NBC activity in A549
cells with (orange open square) or without (control, black open square) SiIRBIT at 48 h. Averaged traces
are presented. (F) The bars indicate the mean ± SEM of data (n = 4). (G) The bars depict the resting
pHi level of A549 cells, which indicate the mean ± SEM of data (n = 30). (H) Surface expression of
NBCn1 in the presence or absence of SiIRBIT in A549 cells. β-Actin and input NBCn1 blots were used
as loading controls (n = 3). (I) Immunostaining images of NBCn1 (red) and nucleus (DAPI, blue) in
the presence or absence of SiIRBIT. Scale bars represent 10 µm. (J) Analysis of NBCn1 expression in
the presence of SiIRBIT in A549 cells. The bars indicate the mean ± SEM of data (n = 6).
3.4. The NBC Inhibitor, S0859, Partially Inhibited Cell Motility
In order to confirm the role of NBC in cell migration, cells were treated with the NBC inhibitor
S0859. It was observed that cell motility following S0859 treatment was approximately 50% lower than
that of the control (Figure 4A,B). However, S0859 did not affect cell viability (Figure 4C). The membrane
localization and surface expression of NBCn1 did not change in the presence of S0859 (Figure 4D–F). We
also confirmed that the activity of NBC was inhibited by S0859 (Figure 4G,H). An acidic environment
is a characteristic feature of cancerous tissues [41–43]. The inhibitory role of S0859 on the migration
of cancer cells to an acidic environment was confirmed by the transwell assay, performed at normal
physiological pH and at acidic pH. The cells migrated toward the bottom chamber, which was at acidic
pH. Cell migration was determined by DAPI staining. The migration of A549 cells was enhanced
under acidic conditions and reduced by S0859 treatment (Figure 4I,J). These results suggested that
S0859 partially inhibited cell motility by attenuating the activity of NBC and not by altering the protein
expression of NBCn1.Pharmaceutics 2020, 12, x 10 of 19 
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S0859 for 72 h. (D) Immunostaining images of NBCn1 (red) and nucleus (DAPI, blue) in the presence
of S0859 at 24 h. Scale bars represent 10 µm. (E) Surface expression of NBCn1 24 h after treatment with
20 µM S0859. IRBIT, β-Actin, and input NBCn1 were used as loading controls. (F) The bars indicate
the mean ± SEM of relative NBCn1 int nsity normaliz d by input NBCn1 (n = 3). (G) NBC activity
in A549 cells with (green open square) or without (control, black open square) 20 µM S0859 at 24 h.
Averaged traces are presented. (H) Bars indicate the mean ± SEM of NBC activity (n = 3). (I) A549
migration was measured by a transwell membran migration assay. The cells wer incubated with
the media and reagents indicated her after (bottom chamber: media o pH 7.8 and pH 6.5; upper
chamber: with or witho t 20 µM S0859). Immunofluorescence staining of DAPI represents blue color.
Scale bars represent 50 µm. (J) Analysi of the to al intensity of DAPI or determini g A549 cell
migration. The bars repr sent the mean ± SEM of data (n = 4).
3.5. NBCn1 Knockdown Reduced Cell Motility
To confirm the role of NBCn1 in cell motility, the cells were treated with SiRNA-NBCn1. The efficacy
of SiRNA-NBCn1 was evaluated by Western blotting (Figure 5A,B). It was observed that the expression
of IRBIT was independent of NBCn1 knockdown (Figure 5A,C). Membrane localization of NBCn1
decreased in the presence of SiRNA-NBCn1 (Figure 5D,E). NBCn1 knockdown dramatically inhibited
the activity of NBC (Figure 5F,G). In order to verify the role of NBCn1 on the invasive motility of cancer
cells, migration of the invasive A549 cells into the agarose spots was compared between the control
and NBCn1 knockdown conditions. Invasive motility of the cancer cells was inhibited following
NBCn1 knockdown (Figure 5H,I). The reduced migration in the presence of SiRNA-NBCn1 was also
observed in other cancer cell line MCF-7, breast cancer cell line (Supplementary Figure S4A–C). These
results suggest that NBCn1 is involved in cell migration. In addition, knockdown of NBCn1 or IRBIT
(Supplementary Figure S5A–D) and overexpression of NBCn1 or IRBIT (Supplementary Figure S6A,B)
did not affect the expression of epithelial–mesenchymal transition markers.
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3.6. IRBIT Expression Preserved the Expression of NBCn1 in the Plasma Membrane
Epidermal growth factor (EGF)/EGF receptor (EGFR) signaling is a key factor in tumor growth
and the development of metastasis, and is considered a target for chemotaxis in cancer therapy [44–47].
In order to explore the role of EGF signaling on cell migration, migration of invasive A549 cells into
agarose spots was compared between EGF (recombinant human EGF)-treated and control conditions,
and between IRBIT-overexpressed and IRBIT-knockdown conditions (Figure 6A). Invasive motility of
the cells following EGF treatment was found to be approximately 1.4-fold higher than that of the control
(Figure 6B). IRBIT overexpression had additive effects with EGF whereas IRBIT knockdown inhibited
cell migration even in presence of EGF (Figure 6C). To evaluate the role of EGF in NBCn1 expression,
the A549 cells were immunostained with NBCn1 in presence of EGF. Treatment with EGF revealed
the enhanced expression of NBCn1 in the plasma membrane (Figure 6D). EGF treatment enhanced
the expression of NBCn1 and IRBIT in the plasma membrane (Figure 6E,F). Migratory ability of the cells
in the transwell assay performed using DAPI (Figure 6G,H) and crystal violet (Supplementary Figure
S7A,B) was further confirmed by the results of the agarose spot assay following EGF treatment. These
results indicated that IRBIT maintained NBCn1 expression and modulated EGF signaling, which is
necessary for cell migration.
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PBS (pH 7.4) and 20 ng/mL EGF, along with IRBIT and SiRNA-IRBIT (SiIRBIT) for indicated times.
(B,C) Analysis of the migration range per hour. The bars indicate the mean ± SEM of data (n = 4). (D)
Immunostaining images of NBCn1 (red) and nucleus (DAPI, blue), in the presence or absence of 20
ng/mL EGF in A549 cells. The scale bars of the magnified images represent 20 µm. (E) Immunostaining
images of IRBIT (red), nucleus (DAPI, blue), and NBCn1 (green) in the presence or absence of 20 ng/mL
EGF in A549 cells. The scale bars of the magnified images represent 10 µm. (F) The bars indicate
the mean ± SEM of NBCn1 intensity per membrane fraction (n = 4). (G) A549 migration was measured
by a transwell membrane migration assay. The cells were incubated with reagents indicated hereafter
(bottom chamber: with or without 20 ng/mL EGF; upper chamber: with empty vector [EV, Control],
IRBIT, and SiIRBIT). Immunofluorescence staining images with DAPI (blue). The scale bars represent
50 µm. (H) Analysis of the total intensity of DAPI for A549 migration. The bars present the mean ±
SEM of data (n = 4).
3.7. Combined Inhibition of CaMKII and NBC Markedly Inhibited Cell Migration
IRBIT functions downstream of CaMKII, and is phosphorylated by the CaMKII protein [1,6]. To
evaluate therapeutic candidates that target cell migration by inhibiting the phosphorylation of IRBIT,
the cells were treated with the NBC inhibitor S0859, CaMKII inhibitor KN93 [34], and a combination
of both inhibitors. Migration of A549 cells was observed by DAPI (Figure 7A,B) and crystal violet
staining (Supplementary Figure S8A,B), which revealed that cell migration was dramatically reduced
by the combined treatment. The protein expression of NBCn1 was reduced by KN93 and combined
treatment, respectively (Figure 7C,D). The protein expression of IRBIT was reduced by presence of
KN93 (Figure 7C,E). To confirm the role of KN93 on NBCn1 expression, cells were treated with KN93.
The inhibitory role of KN93 was revealed by a reduction in the expression of NBCn1 in the membrane
and in protein expression of NBCn1 (Figure 7F,G). The expression of NBCn1 was dose-dependently
reduced by the treatment of KN93 (Figure 7H,I), whereas KN93 alone did not affect the expression of
IRBIT protein (Figure 7H). We also confirmed the role of CaMKII on NBCn1 with KN62 as a structural
shared form of KN93. Migration was reduced in presence of KN62, whereas combined treatment
with S0859 showed no additive effect on migration (Supplementary Figure S9A,B). KN62 treatment
and combined treatment did not affect the expression of NBCn1 and IRBIT protein (Supplementary
Figure S9C). These results suggest that NBCn1 is necessary for cell migration with involvement of
CaMKII/IRBIT pathway.
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Figure 7. Combined inhibition of CaMKII and NBC markedly inhibited cell migration. (A) Migration
of A549 cells was measured by a transwell membrane migration assay. The cells were incubated with
the medium and reagents indicated hereafter (bottom chamber: media of pH 6.5; upper chamber:
pretreatment with KN93 and S0859 at 48 h). Immunofluorescence staining with DAPI (blue). The scale
bars represent 50 µm. (B) Analysis of the total intensity of DAPI for determination of A549 migration.
The bars represent the mean ± SEM of data (n = 4). (C) Protein expression of IRBIT and NBCn1 in
A549 cells in the presence of KN93 and S0859 at 20 µM. β-Actin was used as a loading control. (D)
Analysis of the relative intensity of NBCn1. The bars indicate the mean ± SEM of the intensities of
NBCn1 normalized by β-Actin (n = 3). (E) Analysis of the relative intensity of IRBIT. The bars indicate
the mean ± SEM of the intensities of IRBIT normalized by β-Actin (n = 3). (F) Immunostaining images
of NBCn1 (red) and nucleus (DAPI, blue) in the presence or absence of 20 µM KN93. Scale bars of
the magnified images represent 10 µm. (G) The bars indicate the mean ± SEM of the NBCn1 membrane
determined from three experimental replicates (n = 3). (H) Protein expression of IRBIT and NBCn1 in
A549 cells in the presence of KN93 at 1–40 µM. β-Actin was used as a loading control. (I) Analysis
of the relative intensity of NBCn1. The bars indicate the mean ± SEM of the intensities of NBCn1
normalized by β-Actin (n = 3).
4. Discussion
Taken together, this study clearly demonstrates that the IRBIT protein, which binds to NBCn1,
plays a positive role in the migration of lung cancer cells by maintaining stable NBCn1 expression
in the plasma membrane by mimicking the stimulatory effect of EGF. The illustrated scheme of our
results is represented in Figure 8.
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Figure 8. Schematic illustration of function of NBCn1 as a migration machinery and regulatory factors
on NBCn1-mediated migration in lung cancer cells. IRBIT protein is recruited to NBCn1, plays a positive
role in the migration of lung cancer cells and stored expression of NBCn1 in the plasma membrane
as a stimulated condition with EGF. NBC inhibitor S0859, knockdown of NBCn1 or IRBIT, CaMKII
inhibitor KN93 attenuate the NBCn1-mediated cellular migration.
The role of IRBIT in tumor progression is paradoxical in that its nuclear expression has been
shown to have a tumor-promoting role in chicken ovarian cancer cells but a tumor-suppressive role in
human epithelial ovarian cancer cells [48]. Genomic fusion of fibroblast growth factor and IRBIT has
been demonstrated in patients with cholangiocarcinoma [49]. However, IRBIT antagonizes the Bcl-2
oncogene [50] and is considered a tumor suppressor protein. Although the regulatory role of IRBIT
on the expression of oncogenes and subsequent carcinogenesis is yet unknown and requires further
investigation, our results demonstrate that the effect of IRBIT on the activity of ion transporters has
a prominent role in cancer cell migration. It has been demonstrated that IRBIT interacts with and
regulates the activity of ion transporters, such as NBCe1-B [51], CFTR [2,30], SLC26A6 [30], and
NHE3 [52]. Enhanced expression and activity of NBCn1 have been demonstrated in breast cancer and
the development of cancer [26,27]. Modulation of pH at the tumor microenvironment and the cancer
metastasis are associated with the activity of ion transporters and channels [53,54].
The results of this study clearly demonstrate that the modulatory effect of IRBIT on the ion
transporter NBCn1 enhanced cancer cell migration. IRBIT knockdown revealed that the cells had
a greater tendency to migrate toward an acidic pH, compared to that of the cells in the control
setup. These results demonstrate that stable NBCn1 expression was suppressed by the reduced IRBIT
expression and the reduction in NBCn1 expression was associated with insufficient bicarbonate influx,
which caused the cytosolic pH to become acidic, as depicted in Figure 3G. As depicted in Figure 6E,F,
stimulation by EGF induced NBCn1 overexpression, but not that of IRBIT; however, recruitment of
IRBIT to NBCn1 was enhanced by stimulation with EGF. It can therefore be assumed that oncogenic
chemotactic signals may facilitate the expression of transporter proteins.
Moreover, the membrane expression of the enhanced transporter proteins is also maintained
by the recruited IRBIT. It has been suggested that IRBIT is localized in membrane and cytosolic
fraction [55]. The molecular mechanism of IRBIT on modulation of NBCn1 can be inferred by
the interaction between IRBIT and NBCe1-B [5], and our previous report suggested that positively
charged N-terminal domain of NBCe1-B interacts with negatively charged domain of IRBIT [2,31].
IRBIT recruits protein phosphatase 1 for activation and phosphorylation by STE20/SPS1-related kinase
(SPAK) inhibits NBCe1-B. Convergent regulation occurred in the N-terminal domain of NBCe1-B.
Homology between the N-terminal domains of NBCe1-B and NBCn1 predicts their similar molecular
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interaction with IRBIT. Thus, the role of IRBIT such as in phosphatase recruitment and kinase inhibition
(e.g., SPAK) may also mediate stable membrane expression of NBCn1 [2,31].
It was notable that the effects of combined treatment with the CaMKII inhibitor KN93 and
NBC inhibitor S0859 were more dramatic than those following treatment with the S0859 alone. One
possibility could be that IRBIT recruits various receptors and transporters and thereby regulates a wide
range of transporters, including NBCn1 [1]. Additionally, the IRBIT protein was ubiquitously detected
in most of tissues such as lung, kidney, thymus, ovary, and brain, especially in the cerebrum and
cerebellum [8]. Although we only elucidated the role of IRBIT on NBCn1 transporters in lung cancer
cells, the potential regulatory role of IRBIT on various transporters should be focused on in other types
of cancer tissue. Moreover, in order to precisely understand the modulatory effect of IRBIT on cancer
migration, the dominant transporters and receptors that are necessary for cell migration need to be
studied. Additionally, the molecular mechanism underlying the regulatory effect of IRBIT needs to
be elucidated.
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